Tonix Pharmaceuticals
TNXP
102 hedge funds and large institutions have $119M invested in Tonix Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 8 reducing their positions, and 5 closing their positions.
932% more capital inflows, than outflows
Capital inflows: $64.2M | Capital outflows: $6.22M
538% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 8
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
26% more funds holding
Funds holding: 81 → 102 (+21)
22.37% more ownership
Funds ownership: 36.32% → 58.7% (+22%)
60% less call options, than puts
Call options by funds: $2.02M | Put options by funds: $5.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.4M |
| 2 |
Millennium Management
New York
|
+$9.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$9.31M |
| 4 |
BlackRock
New York
|
+$5.55M |
| 5 |
II
Ishara Investments
Los Angeles,
California
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.52M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.33M |
| 3 |
Quadrature Capital
London,
United Kingdom
|
-$239K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$65.9K |
| 5 |
Morgan Stanley
New York
|
-$26.2K |
TNXP Hedge Fund Activity: Q2 2026 in Review
102 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q2 2026, worth a combined $119M — up 78% from $67M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TNXP positions and 5 closed out — a net gain of 23 holders — while 51 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $13.4M. The largest seller was Citadel Advisors, cutting an estimated $3.52M.
- 102 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $119M of Tonix Pharmaceuticals stock for Q2 2026, up 78% quarter-over-quarter.
- 28 funds opened new Tonix Pharmaceuticals positions in Q2 2026 and 5 closed out, a net change of +23 holders.
- The largest Tonix Pharmaceuticals buyer in Q2 2026 was Point72 Asset Management, an estimated $13.4M added.
- The largest Tonix Pharmaceuticals seller in Q2 2026 was Citadel Advisors, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2026.